Australian Official Journal Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Exempt Services
County of Somerset New Jersey PO Box 3000 – 20 Grove Street COUNTY ADMINISTRATION BUILDING SOMERVILLE, NJ 08876-1262 PURCHASING DIVISION PHONE: (908) 231-7045 MARY LOUISE STANTON Fax: (908) 575-3917 Purchasing Agent, QPA NOTICE TO BIDDERS #2 SOCCP The County of Somerset is conducting a voluntary Co-operative Pricing System #2 SOCCP. Sealed bids which will be received by the Purchasing Agent acting as Lead Agent on behalf of each participating contracting unit, on January 26, 2010 at 2:30 P.M. prevailing time in the Purchasing Division, County Administration Building, 20 Grove St., Somerville, NJ 08876 at which time and place bids will be opened and read in public for: Uniforms, Various County Departments, Contract #CC-04-10 Proposals must be made on the standard proposal form, in addition to a CD of the Table, be enclosed in a sealed package. Specifications and instruction to bidders may be obtained at the Purchasing Office or the County website at www.co.somerset.nj.us * * All Bid Addenda will be issued on the website. Therefore, all interested respondents should check the website from now through bid opening. It is the sole responsibility of the respondent to be knowledgeable of all addenda related to this procurement. Bidders shall comply with the requirements of N.J.S.A. 10:5-31 and N.J.A.C. 17-27 et seq. Mary Louise Stanton, QPA NOTICE- RESULTS OF ALL BIDS ARE POSTED ON THE COUNTY WEB SITE. 1 CO-OPERATIVE PRICING CONDITIONS METHOD OF AWARDING CONTRACTS Contract(s) of purchase shall be awarded to the lowest responsible bidder(s) as declared by the County of Somerset. -
Invitation to Bid Fire Uniforms ITB # 269-2015-059 Charlotte/Mecklenburg County
Invitation to Bid Fire Uniforms ITB # 269-2015-059 Charlotte/Mecklenburg County Phase 2 May 21, 2015 1:00PM Galls, LLC ® --- Table of Contents ITB # 269-2015-059 Fi re Uniforms Charlotte/Mecklenburg County Phase 2 o Form 1- Bid Submission Form o Form 2 -Acknowledgement of AddendumsjExceptions Form o Form 3- Pricing Sheet o Form 4- Nondiscrimination Certification Form o Form 5- E Verify Certification o Form 6- Solicitation Schedule o CCPA Plan- Attachment 3 o Product Specifications- Attachment 4 o Billing Capabilities- Attachment 6 o Procurement Cards- Attachment 7 o Pricing Sheet (PDF Version) o Addendums o Description of Exact Products Bid (Specs) (]L\RLOTTE. Section 6 Required Forms - Form One BID SUBMISSION FORM ITB # 269-2015-059 FIRE UNIFORMS This Bid is submitted by: Company Name: _G=a:::.Bs;:;.!,-=L=-=L:.;:C::...._ ______________ _ Representative (printed): _D,-a_r_n_ell_D_e_n_n-.::is_ ------------ Representative (sigued) : [J~ J) ~- Address: 1340 Russell Cave Road City/State/Zip: Lexington KY 40505 Telephone: 800-876-4242 x 2356 (Area Code) Telephone Number Facsimile: 877-914-2557 (Area Code) Fax Number E-Mai I Address: [email protected] It is understood by the Bidder that the CL T reserves the right to reject any and all Bids, to award multiple Contracts by line item, combination of items, or grand total on a state, regional, or national basis according to the best interest of the CL T and CCPA, to waive formalities. technicalities, to recover and re-bid this ITB. Bids are valid for one hundred twenty ( 120) calendar days from Bid Opening. Galls, LLC 4/7/15 Date Darnell Dennis Aut or1zed S1gnature Please type or print name ITB 269-2015-059 MARCH 23, 2015 37 45 Section 6 Required Forms- Form Two Addenda Acknowledgement I Exceptions Form ITB # 269-2015-059 FIRE UNIFORMS Bid/Bid Submission Check List: Confim1 by placing a check mark in the space provided that as the bidder or proposer the infom1ation listed belov. -
Fibrolase: Trials and Tribulations
Toxins 2010, 2, 793-808; doi:10.3390/toxins2040793 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Review Fibrolase: Trials and Tribulations Francis S. Markland 1,2,* and Steve Swenson 1,2 1 Department of Biochemistry and Molecular Biology, Cancer Research Laboratory, Keck School of Medicine, University of Southern California, 1303 N. Mission Rd., Los Angeles, CA 90033, USA 2 USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-(323) 224-7981; Fax: +1-(323) 224-7679. Received: 11 March 2010; in revised form: 31 March 2010 / Accepted: 19 April 2010 / Published: 20 April 2010 Abstract: Fibrolase is the fibrinolytic enzyme isolated from Agkistrodon contortrix contortrix (southern copperhead snake) venom. The enzyme was purified by a three-step HPLC procedure and was shown to be homogeneous by standard criteria including reverse phase HPLC, molecular sieve chromatography and SDS-PAGE. The purified enzyme is a zinc metalloproteinase containing one mole of zinc. It is composed of 203 amino acids with a blocked amino-terminus due to cyclization of the terminal Gln residue. Fibrolase shares a significant degree of homology with enzymes of the reprolysin sub-family of metalloproteinases including an active site homology of close to 100%; it is rapidly inhibited by chelating agents such as EDTA, and by alpha2-macroglobulin (). The enzyme is a direct-acting thrombolytic agent and does not rely on plasminogen for clot dissolution. Fibrolase rapidly cleaves the A()-chain of fibrinogen and the B()-chain at a slower rate; it has no activity on the -chain. -
Izzy. and We’Re All Here
ALSO BY CELESTE NG Everything I Never Told You PENGUIN PRESS An imprint of Penguin Random House LLC 375 Hudson Street New York, New York 10014 penguin.com Copyright © 2017 by Celeste Ng Penguin supports copyright. Copyright fuels creativity, encourages diverse voices, promotes free speech, and creates a vibrant culture. Thank you for buying an authorized edition of this book and for complying with copyright laws by not reproducing, scanning, or distributing any part of it in any form without permission. You are supporting writers and allowing Penguin to continue to publish books for every reader. ISBN 9780735224292 (hardcover) ISBN 9780735224308 (eBook) ISBN 9780525522560 (international edition) This is a work of fiction. Names, characters, places, and incidents either are the product of the author’s imagination or are used fictitiously, and any resemblance to actual persons, living or dead, businesses, companies, events, or locales is entirely coincidental. Version_2 To those out on their own paths, setting little fires CONTENTS ALSO BY CELESTE NG TITLE PAGE COPYRIGHT DEDICATION EPIGRAPH CHAPTER 1 CHAPTER 2 CHAPTER 3 CHAPTER 4 CHAPTER 5 CHAPTER 6 CHAPTER 7 CHAPTER 8 CHAPTER 9 CHAPTER 10 CHAPTER 11 CHAPTER 12 CHAPTER 13 CHAPTER 14 CHAPTER 15 CHAPTER 16 CHAPTER 17 CHAPTER 18 CHAPTER 19 CHAPTER 20 ACKNOWLEDGMENTS Whether you buy a homesite in the School Section, broad acres in the Shaker Country Estates, or one of the houses offered by this company in a choice of neighborhoods, your purchase includes facilities for golf, riding, tennis, boating; it includes unexcelled schools; and it includes protection forever against depreciation and unwelcome change. -
Guidelines on CVD During Pregnancy (TF17) - Task Force Members and Additional Contributors
Guidelines on CVD during Pregnancy (TF17) - Task Force Members and Additional Contributors Expert Relationship Type of relationship with industry Financial declaration with Industry Blomstrom-Lundqvist Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. Carina - Medtronic : Pacemaker B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Atricure : AF ablation Borghi Claudio Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini International : ACE-inhibitors - Boheringer Ingelheim : Antihypertensive drugs - Recordati International : Antihypertensive drugs - Novartis : Antihypertensive, Heart Failure D - Research funding (departmental or institutional). - Barilla Food Company : Lactotripeptides Cifkova Renata Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : cardiovascular - Daiichi Sankyo : cardiovascular - MSD-SP, Boehringer Ingelheim, Bayer : cardiovascular B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : cardiovascular - Novartis : cardiovascular D - Research funding (departmental or institutional). - Krka Czech Republic : cardiovascular - Servier Czech Republic : cardiovascular Ferreira J Rafael No -
Elejq . 5W4” \/ Inventor
Jan. 29, 1963 ' C..RUBIO 3,075,202 PIN COLLAR STAYS Filed June 13, 1955 8 , \ / 7 3 .ELEJQ . 5W4” \/ INVENTOR. 5. [40 I5 4 Carlos Ruble 3,b75,2d2 United States Patent 0 " 1C6 Patented Jan. 29, 1353 1 2 FIGURE 7 is a plan view showing a modi?ed form of 3,075,202 angular adjustable stay for collars. PIN COLLAR STAYS FIGURE 8 is a plan view showing a modi?ed form of Carlos Rubin, 126 E. 83rd St, New York, N.Y. cross adjustable collar stay, according to the invention. Filed June 13, 1955, Ser. No. 514,840 FIGURE 9 is a plan view showing another modi?ed 2 Claims. (El. 2-132) form of collar stay with unitary main body construction. FIGURE 10 is a front elevational view of the collar This invention relates to improvements in devices for stay shown in FIGURE 9. staying and smoothing shirt collars and the like. FIGURE 11 is a right end-elevational View of the collar An object of the invention is to provide a novel and im stay shown in FIGURE 9. proved shirt collar stay which is carried by the collar in FIGURE 12 is a plan view showing another modi?ed order to retain the collar in unwrinkled form, and with a form of quadrilateral stay of a type suitable for collars smooth attractive appearance. also. ' Another object of the invention is to provide a novel The presently disclosed devices are convenient for main and improved shirt collar stay which may be employed on 15 taining the most attractive and uniform appearance de any type of shirt collar, whether or not it is equipped sired in connection with the wearing of shirt collars. -
20Oo.4 (217, 4- Y 21 Arroa M/ Sys Patented Apr
April 29, 1952 W. R. STORY 2,595,112 ADHESIVE COLLAR STAY PACKAGE Filed Oct. 15, 1949 INVENTOR, BY 20oo.4 (217, 4- y 21 arroa M/ sys Patented Apr. 29, 1952 2,595,112 UNITED STATES PATENT OFFICE 2,595,112 ADHES WE COLLAR STAY PACKAGE Walter R. Story, Bellevue, Ky. Application October 15, 1949, Serial No. 121,589 2 Claims. (C. 206-56) 1 s 2 This invention relates to shirt collar stays . Sequently, it will be apparent that the use of and is particularly directed to a self-supporting stays of this type will not only permit a material adhesive stay adapted for use with practically reduction in the manufacturing cost of shirts, any make or style of collar and which may be but the Wearing life of the Shirts Will be sub repeatedly used and re-used on the same shirt stantially prolonged. The stays of this inven Or on different shirts for a great number of tion are adapted for repeated use with the same WearingS. shirt or different shirts having a variety of collar In Order to prevent starched and soft collars styles for a great number of wearings. Thus, from curling and wrinkling, it has been conven in the event that a stay becomes mislaid or lost, tional to stiffen and support the collar wings by 10 it can be easily replaced with a similar stay means of elongated Stays or ribs which are re Without necessitating the construction of a movably held in cloth pockets formed on the substitute fitted to a particular collar pocket. -
In Re Nuvelo, Inc. Securities Litigation 07-CV-04056-Declaration of Mark
BERGER & MONTAGUE, P.C. Sherrie R. Savett Carole A. Broderick Phyllis M. Parker 1622 Locust Street Philadelphia, PA 19103 Tel: (215) 875-3000 Fax: (215) 875-4604 Email: [email protected] cbroderick@bm ,net [email protected] IZARD NOBEL LLP ROBBINS GELLER RUDMAN Jeffrey S. Nobel & DOWD LLP Mark P. Kindall, Bar No 138703 Darren J. Robbins Nancy A. Kulesa Dennis J. Herman 29 South Main Street Eli R. Greenstein Suite 215 S. Ashar Ahmed West Hartford, Ct 06107 Post-Montgomery Center Tel: (860) 493-6292 One Montgomery Street, Suite 1800 Fax: (860) 493-6290 San Francisco, CA 94104 Email: [email protected] Tel: (415) 288-4545 [email protected] Fax: (415) 288-4534 [email protected] Email: [email protected] dennisb@rgrdlaw,corn [email protected] aahmed@rgrdlaw com Co-Lead Counsel for Plaintiffs Liaison Counsel UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA SAN FRANCISCO DIVISION In re NUVELO, INC. SECURITIES Master File No 07-CV-04056-VRW LITIGATION CLASS ACTION DECLARATION OF MARK P. KINDALL IN SUPPORT OF PLAINTIFFS' MOTION FOR CLASS CERTIFICATION DATE: March .3, 2011 I TIME: 10:00 a.rn. I COURTROOM: 6 DECLARATION OF MARK P KINDALL IN SUPPORT OF PLArNTIFFS' MOTION FOR CLASS CERTIFICATION - 07-CV-04056-VRW DECLARATION OF MARK P. KINDALL IN SUPPORT OF PLAINTIFFS' MOTION FOR CLASS CERTIFICATION 2 3 I, Mark P. Kindall, hereby declare as follows: 4 1. I am a partner at the law firm of Izard Nobel LLP, which was appointed Co-Lead 5 Counsel for Plaintiffs in this litigation on September 19, 2007. I have personal knowledge of the 6 facts set forth herein. -
The Development of Stroke Therapeutics: Promising Mechanisms and Translational Challenges
Neuropharmacology 56 (2009) 329–341 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Review The development of stroke therapeutics: Promising mechanisms and translational challenges Margaret M. Zaleska a, Mary Lynn T. Mercado a, Juan Chavez b, Giora Z. Feuerstein b, Menelas N. Pangalos a, Andrew Wood a,* a Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA b Translational Medicine, Wyeth Research, Collegeville, PA, USA article info abstract Article history: Ischemic stroke is the second most common cause of death worldwide and a major cause of disability. Received 8 August 2008 Intravenous thrombolysis with rt-PA remains the only available acute therapy in patients who present Received in revised form within 3 h of stroke onset other than the recently approved mechanical MERCI device, substantiating the 29 September 2008 high unmet need in available stroke therapeutics. The development of successful therapeutic strategies Accepted 6 October 2008 remains challenging, as evidenced by the continued failures of new therapies in clinical trials. However, significant lessons have been learned and this knowledge is currently being incorporated into improved Keywords: pre-clinical and clinical design. Furthermore, advancements in imaging technologies and continued Ischemia Neuroprotection progress in understanding biological pathways have established a prolonged presence of salvageable Regeneration penumbral brain tissue and have begun to elucidate the natural repair response initiated by ischemic Inflammation insult. We review important past and current approaches to drug development with an emphasis on Neuroimaging implementing principles of translational research to achieve a rigorous conversion of knowledge from Translational medicine bench to bedside. We highlight current strategies to protect and repair brain tissue with the promise to Drug development provide longer therapeutic windows, preservation of multiple tissue compartments and improved clinical success. -
The Bottom 99
The Top 100 June 1, 2004 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. ABFI AMER BUSINESS FINL SVCS INC Financials ABGX ABGENIX INC Health Care ADLR ADOLOR CORP Health Care AGEN ANTIGENICS INC/DEL Health Care AGI ALLIANCE GAMING CORP Consumer Cyclicals AKLM ACCLAIM ENMNT INC Technology ALKS ALKERMES INC Health Care ALXN ALEXION PHARMACEUTICALS INC Health Care AMLN AMYLIN PHARMACEUTICALS INC Health Care APHT APHTON CORP Health Care ARNA ARENA PHARMACEUTICALS INC Health Care BIOV BIOVERIS CORP Health Care BMRN BIOMARIN PHARMACEUTICAL INC Health Care BVSN BROADVISION INC Technology CBRX COLUMBIA LABORATORIES INC Health Care CCRD CONCORD COMMUNICATIONS INC Technology CDE COEUR D'ALENE MINES CORP Basic Materials CFFN CAPITOL FEDERAL FINANCIAL Financials COMS 3COM CORP Technology CPN CALPINE CORP Utilities CRAY CRAY INC Technology CRGN CURAGEN CORP Health Care CRXA CORIXA CORP Health Care CYBX CYBERONICS INC Health Care DAL DELTA AIR LINES INC Capital Goods DEPO DEPOMED INC Health Care DMX I-TRAX INC Health Care DRXR DREXLER TECHNOLOGY CORP Technology DSCO DISCOVERY LABORATORIES INC Health Care DV DEVRY INC Capital Goods ELGX ENDOLOGIX INC Health Care EPIX EPIX MEDICAL INC Health Care EXEL EXELIXIS INC Health Care EXLT EXULT INC Capital Goods FCP FALCON PRODUCTS INC Capital Goods FMKT FREEMARKETS INC Technology FXEN FX ENERGY INC Energy GBTVK GRANITE BROADCASTING Consumer Cyclicals GENE OSCIENT PHARMACEUTICALS CORP Health Care GGNS GENUS INC Technology GLFD GUILFORD PHARMACEUTICAL INC Health Care GMRK GULFMARK OFFSHORE -
Healthcare Conference
25th Annual HEALTHCARE CONFERENCE Healthcare Westin St. Francis San Francisco January 8–11, 2007 JPMorgan cordially invites you to attend the 25th Annual Healthcare Conference, January 8 –11, 2007, at the Westin St. Francis in San Francisco. JPMorgan’s premier conference on the healthcare industry will feature more than 260 public and private companies over four days of simultaneous sessions. In addition, the conference will host topical panel discussions featuring leading industry experts. Preliminary List of Invited Presenting Companies Actelion Ltd Baxter International Inc. Cooper Companies Aetna Incorporated BD (Becton, Dickinson) Coventry Affymetrix, Inc. Beckman Coulter, Inc. Dade Behring Holdings, Inc. Alcon, Inc. Bioenvision, Inc. DaVita Inc. Align Technology, Inc. Biogen Idec deCODE genetics, Inc. Allscripts Healthcare Solutions Inc. Biomet, Inc. Digene Altana Boston Scientific Corporation Digirad Corporation — US American Medical Systems Holdings Inc. Bristol-Myers Squibb Company Diversa Corporation Amerigroup Corp. Cambrex Corporation DJO Incorporated AmerisourceBergen Cardinal Health, Inc. Dyax Corp. Amgen, Inc. Caremark Rx, Inc. Eclipsys Corporation AMN Healthcare Services, Inc. Celgene Corporation Edwards Lifesciences Corporation AmSurg Corporation Cell Genesys Elan Corporation, plc Anadys Pharmaceuticals CENTENE Corporation Eli Lilly and Company Applied Biosystems Group Cephalon, Inc. Emdeon Ariad Pharmaceuticals, Inc. Cerner Corporation Emergency Medical Services Corporation AstraZeneca Group plc Charles River Laboratories, -
Schedule 14A Information
QuickLinks -- Click here to rapidly navigate through this document SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to §240.14a-12 GILEAD SCIENCES, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0- 11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: GILEAD SCIENCES, INC.